Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

Table 6 Characteristics of studies included based on treatment regiments: carboplatin + standard NACT + PARPi

	Affiliation	Type of study	Stage of disease	Nº of BRCA1/2 mutated TNBC patients	pCR	Neoadjuvant treatment
Severson 2017 [46]	Holand	Multicenter phase II trial	II-III	32	17	Cb-P–V + Dox-C
Loib 2018 BrighTNess [37]	USA	Multicenter, RCT phase III trial	II-III	46	26	Cb-P–V + Dox-C
Litton 2017 [47]	USA	pilot trial,	I-III	5	3	Cb-P–T-Dox-C

pCR Pathological complete response, Cb Carboplatin, Dox Doxorubicin, C Cyclophosphamide, P Paclitaxel, V Veliparib, T Talazoparib

ISSN: 1897-4287